Effects of Nature and Forest Therapy in Patients With Metabolic Syndrome and Cardiovascular Risk Factors

NCT ID: NCT04781491

Last Updated: 2023-10-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-27

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to investigate the effects of regular forest therapy under guidance of a licensed nature therapist on patients with metabolic syndrome and cardiovascular risks

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is assumed that nature and forest experience has sustainable benefits for the physical and mental health of individuals with metabolic syndrome and cardiovascular risk profile. Especially co-therapeutic effects in terms of resilience and salutogenesis might effectively and sustainably promoted by nature and forest therapy.

The main objective of this study is to measure the effects of nature and forest therapy in subjects with manifest metabolic syndrome and cardiovascular risk factors. The intervention is a stay in the nature of the Düppeler Forest (Berlin-Wannsee) under the guidance of trained nature guides (90 minutes, 1x/week over 2 months), who teach exercises on the perception of nature and the connection between nature and health, movement and mindfulness. Subjects are also motivated to experience forest nature as regularly as possible (recommended ≥ 30 minutes daily). Participants of the control group will be offered a later participation in the therapy program after completion of the last study visit after 4 months (waiting list control group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome, Protection Against

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Forest Therapy (Düppeler Forst - Berlin-Wannsee)

Subjects receive a 90-minute Forest Therapy session once per week for 8 weeks with a licensed nature therapist, who explains exercises on perceiving nature and the connection between nature and health.

Group Type EXPERIMENTAL

Forest Therapy (Düppeler Forst - Berlin-Wannsee)

Intervention Type BEHAVIORAL

Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna

Waiting list

Subjects don't receive any therapy but are offered the same treatment after trial is finished.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Forest Therapy (Düppeler Forst - Berlin-Wannsee)

Forest Therapy means mindful visits in nature, actively perceiving the flora and fauna

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Definition of Metabolic Syndrome according to the International Diabetes Foundation (IDF):
* waist circumference: at least 94 cm for men, at least 80 cm for women
* plus at least two of the following risk factors:
* fasting blood glucose levels of \> 100 mg/dl (\> 5.6 mmol/l) measured in blood plasma or diagnosed diabetes mellitus
* elevated triglycerides \> 150 mg/dl (\> 1.7 mmol/l) or therapy already initiated to lower triglycerides
* low HDL cholesterol: \< 40 mg/dl (\< 1.05 mmol/l) in men and \< 50 mg/dl (\< 1.25 mmol/l) in women or already initiated therapy to increase HDL
* Hypertension (from \> 130 mmHg systolic and \> 85 mmHg diastolic) or already treated hypertension

Exclusion Criteria

* Serious acute or chronic illnesses
* Immobility or limitation of mobility due to orthopedic, neurological or other medical cause
* Participation in another study
* Serious mental illness
* Pregnancy and lactation
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Charite University, Berlin, Germany

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Andreas Michalsen

Prof.Dr.med

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Michalsen, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Charité Hochschulambulanz für Naturheilkunde am Immanuel Krankenhaus

Berlin, , Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Miriam Rösner

Role: CONTACT

00493080505682

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Miriam Rösner, study nurse

Role: primary

00493080505682

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Wald

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effort During Resistance Training in Type 2 Diabetes
NCT06497842 ACTIVE_NOT_RECRUITING NA